Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
The World's Greatest Investing Community
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Great product without the downside risks of drugs. Increasing contracts with other drug companies for use of their genetic tests for the drug co's drug trials. The future of medicine is personalized based on each inidividual.